Ghatnekar, O <br/><br/>
Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandiŽ) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC).  [electronic resource] 

 -  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research  Nov 2014 
 - A648 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1524-4733 
<br/><br/><label>Standard No.: </label>10.1016/j.jval.2014.08.2350  doi